Fondo Bibliografico Internacional Diciembre 2005
3.- Enfermedad hepática alcohólica, hígado
graso y esteatohepatitis no alcohólica.
Microarray technology in the study
of obesity and non-alcoholic fatty liver disease. Baranova A, Schlauch K,
Gowder S, Collantes R, Chandhoke V, Younossi ZM. Liver International 2005;25:1091-6.
Revisión.
Abnormal glucose tolerance is a predictor
of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver
disease. Willy Haukeland J, Konopski Z, Linnestad P, Azimy S, Marit Loberg
E, Haaland T, Birkeland K, Bjoro K. Scandinavian Journal of Gastroenterology
2005;40:1469-77.
La intoleracia a la glucosa se relaciona con la presencia de hepatitis y fibrosis
en la esteatosis no alcohólica.
Spectrum of NAFLD and diagnostic implications
of the proposed new normal range for serum ALT in obese women. Prati D, Colli
A, Conte D, Colombo M. Hepatology 2005;42:1460-1.
Carta.
NAFLD treatment: Cognitive-behavioral
therapy has entered the arena. Marchesini G, Suppini A, Forlani G. Journal
of Hepatology 2005;43:926-8.
Editorial.
Effect of changes on body weight and
lifestyle in nonalcoholic fatty liver disease. Suzuki A, Lindor K, Saver JS,
Lymp J, Mendes F, Muto A, Okada T, Angulo P. Journal of Hepatology 2005;43:1060-6.
Efectos beneficiosos de la perdida de peso de al menos un 5% y del ejercicio
regular en pacientes con un hígado graso no alcohólico.
Nrf1 gene expression in the liver: A single gene
linking oxidative stress to NAFLD, NASH and hepatic tumours. Parola M, Novo
E. Journal of Hepatology 2005;43:1096-7.
Editorial.
